{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:29:25Z","timestamp":1775485765443,"version":"3.50.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005064","name":"Hebei Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["236Z7741G"],"award-info":[{"award-number":["236Z7741G"]}],"id":[{"id":"10.13039\/501100005064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005064","name":"Hebei Province Science and Technology Support Program","doi-asserted-by":"publisher","award":["23372601D"],"award-info":[{"award-number":["23372601D"]}],"id":[{"id":"10.13039\/501100005064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008238","name":"Hebei Provincial Department of Science And Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008238","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["H2025206335"],"award-info":[{"award-number":["H2025206335"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003787","name":"Hebei Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["H2024206004"],"award-info":[{"award-number":["H2024206004"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82303574"],"award-info":[{"award-number":["82303574"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejmech.2026.118618","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T17:14:11Z","timestamp":1770657251000},"page":"118618","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Discovery of 9-arylamino-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline-8-carbonitriles: Potent inducers of immunogenic cell death via colchicine site-targeted microtubule polymerization inhibition"],"prefix":"10.1016","volume":"307","author":[{"given":"Yan","family":"Ma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhangjian","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youyou","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyu","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yabo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kehao","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaijia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbo","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjie","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7392-5448","authenticated-orcid":false,"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.118618_bib1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.annonc.2024.02.006","article-title":"Adding immunotherapy to first-line treatment of advanced and metastatic endometrial cancer","volume":"35","author":"Bogani","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejmech.2026.118618_bib2","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70346","article-title":"Cancer immunotherapy in combination with radiotherapy and\/or chemotherapy: mechanisms and clinical therapy","volume":"6","author":"Wang","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.ejmech.2026.118618_bib3","article-title":"Reinforcing the immunogenic cell death to enhance cancer immunotherapy efficacy","volume":"1878","author":"Yu","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2026.118618_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.21931\/RB\/2019.04.04.2","article-title":"Immunogenic cell death: an opportunity for clinical oncology?","volume":"4","author":"Aguilar-Noriega","year":"2019","journal-title":"Bionatura"},{"key":"10.1016\/j.ejmech.2026.118618_bib5","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.118618_bib6","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1038\/s41419-020-03221-2","article-title":"Detection of immunogenic cell death and its relevance for cancer therapy","volume":"11","author":"Fucikova","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2026.118618_bib7","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41423-024-01245-8","article-title":"Immunogenicity of cell death and cancer immunotherapy with immune checkpoint inhibitors","volume":"22","author":"Catanzaro","year":"2025","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.ejmech.2026.118618_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.216846","article-title":"Immunogenic cell death inducers:current advances and future perspectives","volume":"542","author":"Lv","year":"2025","journal-title":"Coord. Chem. Rev."},{"key":"10.1016\/j.ejmech.2026.118618_bib9","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2022-CT012","article-title":"Abstract CT012: nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo as neoadjuvant treatment for resectable (IB-IIIA) non-small cell lung cancer (NSCLC): Event-free survival (EFS) results from the phase 3 CheckMate 816 trial","volume":"82","author":"Girard","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118618_bib10","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/onc.2009.356","article-title":"Immunogenic death of colon cancer cells treated with oxaliplatin","volume":"29","author":"Tesniere","year":"2010","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2026.118618_bib11","article-title":"Chemotherapy-induced immunogenic cell death in combination with ICIs: a brief review of mechanisms, clinical insights, and therapeutic implications","volume":"16","author":"Li","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118618_bib12","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1016\/j.cell.2025.02.027","article-title":"Microtubules in Asgard archaea","volume":"188","author":"Wollweber","year":"2025","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2026.118618_bib13","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41420-024-02217-7","article-title":"Mutation of the SUMOylation site of Aurora-B disrupts spindle formation and chromosome alignment in oocytes","volume":"10","author":"Chen","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.118618_bib14","doi-asserted-by":"crossref","first-page":"R728","DOI":"10.1016\/j.cub.2024.06.045","article-title":"Confined migration: microtubules control the cell rear","volume":"34","author":"Thery","year":"2024","journal-title":"Curr. Biol."},{"key":"10.1016\/j.ejmech.2026.118618_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118112","article-title":"Verubulin and its derivatives: progress and promise in tubulin-targeted cancer therapy","volume":"300","author":"Mousavi","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib16","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1080\/15384101.2025.2485842","article-title":"Regulation of microtubule growth rates and their impact on chromosomal instability","volume":"23","author":"Gomes Paim","year":"2024","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ejmech.2026.118618_bib17","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1158\/1538-7445.AM2023-1663","article-title":"Abstract 1663: development of a novel oral microtubule targeting agent with pan-cancer efficacy","volume":"83","author":"Nastke","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118618_bib18","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2009.04.042","article-title":"XN05, a novel synthesized microtubule inhibitor, exhibits potent activity against human carcinoma cells in vitro","volume":"285","author":"Wu","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118618_bib19","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1158\/0008-5472.CAN-08-1342","article-title":"Indibulin, a novel microtubule inhibitor, discriminates between mature neuronal and nonneuronal tubulin","volume":"69","author":"Wienecke","year":"2009","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118618_bib20","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118618_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118191","article-title":"Tubulin-based dual-target compounds and protein degraders for cancer therapy-An updated review (2021-present)","volume":"301","author":"Li","year":"2026","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib22","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib23","article-title":"2023 year in review: early breast cancer","volume":"74","author":"Nader-Marta","year":"2024","journal-title":"Breast"},{"key":"10.1016\/j.ejmech.2026.118618_bib24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.21873\/anticanres.17391","article-title":"Eribulin induction of immunogenic cell Death (ICD): Comparison with other cytotoxic agents and temporal relationship of ICD biomarkers","volume":"45","author":"Zang","year":"2025","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2026.118618_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab vedotin\u2013driven microtubule disruption results in endoplasmic reticulum stress leading to immunogenic cell death and antitumor immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118618_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1124\/pr.56.2.6","article-title":"Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity","volume":"56","author":"Minotti","year":"2004","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2026.118618_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1406247","article-title":"An update of the molecular mechanisms underlying anthracycline induced cardiotoxicity","volume":"15","author":"Xie","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.118618_bib28","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1039\/C8DT00838H","article-title":"The side effects of platinum-based chemotherapy drugs: a review for chemists","volume":"47","author":"Oun","year":"2018","journal-title":"Dalton Trans."},{"key":"10.1016\/j.ejmech.2026.118618_bib29","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.3390\/cancers12051266","article-title":"Assessment and management of platinum-related ototoxicity in children treated for cancer","volume":"12","author":"Romano","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.118618_bib30","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.ejmech.2019.03.025","article-title":"Anti-tubulin agents of natural origin: targeting taxol, vinca, and colchicine binding domains","volume":"171","author":"Naaz","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib31","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.118618_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1158\/1535-7163.MCT-19-0536","article-title":"An orally available tubulin inhibitor, VERU-111, suppresses triple-negative breast cancer tumor growth and metastasis and bypasses taxane resistance","volume":"19","author":"Deng","year":"2020","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2026.118618_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.drup.2023.100951","article-title":"Replacing the tropolonic methoxyl group of colchicine with methylamino increases tubulin binding affinity with improved therapeutic index and overcomes paclitaxel cross-resistance","volume":"68","author":"Yang","year":"2023","journal-title":"Drug Resist. Updates"},{"key":"10.1016\/j.ejmech.2026.118618_bib34","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1021\/acs.jmedchem.3c01775","article-title":"PM534, an optimized target-protein interaction strategy through the colchicine site of tubulin","volume":"67","author":"Lucena-Agell","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib35","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1158\/1078-0432.CCR-11-0937","article-title":"Clinical, pharmacodynamic, and pharmacokinetic evaluation of BNC105P: a phase I trial of a novel vascular disrupting agent and inhibitor of cancer cell proliferation","volume":"17","author":"Rischin","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118618_bib36","doi-asserted-by":"crossref","first-page":"7285","DOI":"10.1021\/jm300564b","article-title":"Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents","volume":"55","author":"Chen","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1200\/jco.2008.26.15_suppl.2531","article-title":"Initial results of a first-in-man phase I study of EPC2407, a novel small molecule microtubule inhibitor anticancer agent with tumor vascular endothelial disrupting activity","volume":"26","author":"Anthony","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118618_bib38","doi-asserted-by":"crossref","first-page":"5865","DOI":"10.1158\/0008-5472.CAN-07-0127","article-title":"MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps","volume":"67","author":"Kasibhatla","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.118618_bib39","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/JTO.0b013e318174e01f","article-title":"A phase II study of ABT-751 in patients with advanced non-small cell lung cancer","volume":"3","author":"Mauer","year":"2008","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2026.118618_bib40","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.2174\/0929867322666150114163732","article-title":"Tubulin colchicine binding site inhibitors as vascular disrupting agents in clinical developments","volume":"22","author":"Ji","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.216046","article-title":"SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis","volume":"555","author":"Deng","year":"2023","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2026.118618_bib42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1423-0127-18-44","article-title":"Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines","volume":"18","author":"Wen","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2026.118618_bib43","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1126\/science.1224922","article-title":"An immunosurveillance mechanism controls cancer cell ploidy","volume":"337","author":"Senovilla","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2026.118618_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810222","article-title":"The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma","volume":"23","author":"Grillone","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.118618_bib45","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/acs.jmedchem.3c02399","article-title":"Discovery of novel isoquinoline analogues as dual tubulin polymerization\/V-ATPase inhibitors with immunogenic cell death induction","volume":"67","author":"Leng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib46","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1002\/jcb.29342","article-title":"Combretastatin analogues in cancer biology: a prospective view","volume":"121","author":"Sherbet","year":"2020","journal-title":"J. Cell. Biochem."},{"key":"10.1016\/j.ejmech.2026.118618_bib47","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.3390\/molecules21111468","article-title":"Current advances of tubulin inhibitors in nanoparticle drug delivery and vascular disruption\/angiogenesis","volume":"21","author":"Banerjee","year":"2016","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.118618_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116543","article-title":"Dual-target inhibitors of colchicine binding site for cancer treatment","volume":"274","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.118618_bib49","article-title":"Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4\/6 inhibitors in HER2-low breast cancer","volume":"42","author":"Chen","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118618_bib50","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1080\/14737140.2017.1338954","article-title":"Neratinib for the treatment of HER2-positive early stage breast cancer","volume":"17","author":"Echavarria","year":"2017","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.118618_bib51","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.ejca.2010.02.032","article-title":"Bosutinib: a review of preclinical studies in chronic myelogenous leukaemia","volume":"46","author":"Boschelli","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2026.118618_bib52","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.2011.38.7522","article-title":"Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial","volume":"30","author":"Cortes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2026.118618_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2025.116783","article-title":"A novel amino-pyrimidine inhibitor suppresses tumor growth via microtubule destabilization and Bmi-1 down-regulation","volume":"233","author":"Gao","year":"2025","journal-title":"Biochem. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000632?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426000632?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T13:39:48Z","timestamp":1775482788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426000632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":53,"alternative-id":["S0223523426000632"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118618","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of 9-arylamino-2,3-dihydro-[1,4]dioxino[2,3-g]quinoline-8-carbonitriles: Potent inducers of immunogenic cell death via colchicine site-targeted microtubule polymerization inhibition","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.118618","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118618"}}